The experience in the diagnostics of hemorrhagic diseases in the period of full-scale Russian-Ukrainian war since 2022 on the example of one specialized state institution

June 27, 2024
128
УДК:  616.151.514-071
Specialities :
Resume

Purpose: to identify the nosological profile of patients with hemorrhagic manifestations, which turned to the State Іnstitution «Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine» since the full-scale war from 24.02.2022.

Objects and methods. 221 persons who turned to the institution, of which 155 (70.1%) were investigated the first time. Coagulation tests were performed by methods that meet international standards and recommendations.

Results. There were first diagnosed 24 (46.2%) patients with hemophilia A, where mild haemophilia A was predominated (79.2%). The mild form (80.0%) also predominated among the first diagnosed hemophilia B patients. For the first time, the diagnosis of Willebrand’s disease was made in 55.5% of patients. All cases of rare bleeding disorders (RBDs) have been detected for the first time, the deficiency of factor VII was the most common.

Conclusion. The number of congenital and acquired coagulopathies, which turned to the SI IBPTM of the UNAMS, has increased with the beginning of the full-scale war from 2022. The posttraumatic bleedings, bleedings after teeth extractions, surgery, soft tissue hemorrhages, mucosal bleedings, menometrorrhagies were the main clinical manifestations in these patients. Joint lesions were rare and mild. The mild forms were dominated among the first detected hemophilia A and B patients. All haemophilia patients were adults, the median was 29 years. The number of diagnosed RBDs patients increased, all cases were first identified.

References

  • 1. www1.wfh.org/publications/files/pdf-2452.pdf.
  • 2. www.orpha.net.
  • 3. Srivastava A., Santagostino E., Dougall A. et al. (2020) WFH Guidelines for the Management of Hemophilia. 3rd Ed. Haemophilia, 26(6): 1–158. doi.org/10.1111/hae.14046.
  • 4. Kitchen S., McCraw A., Echenagucia M. (2010) Diagnosis of haemophilia and other bleeding disorders: A laboratory manual. 2nd Edition. World Federation of Hemophilia (WFH), Montreal, Саnada, 144 p.
  • 5. Красівська В.В., Стасишин О.В., Новак В.Л. (2021) Лабораторна діагностика геморагічних захворювань. КВЩ, Київ, 100 с.
  • 6. Mackie I., Cooper P., Lawrie A. et al. (2013) On behalf of British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int. J. Lab. Hematol., 35(1): 1–13. DOI: 10.1111/bjh.16776.
  • 7. Miller C.H. (2018) Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia, 24(2): 186–197. DOI: 10.1111/hae.13424.
  • 8. Duncan E., Collecutt M., Street A. (2013) Nijmegen- Bethesda assay to measure factor VIII inhibitors. Methods Mol. Biol., 992: 321–333. DOI: 10.1007/978-1-62703-339-8_24.
  • 9. Favaloro E.J., Verbruggen B., Miller C.H. (2014) Laboratory testing for factor inhibitors. Haemophilia, 20(s4): 94–98. DOI: 10.1111/hae.12408.
  • 10. www1.wfh.org/publications/files/pdf-2342.pdf.
  • 11. Connell N.T., Flood V.H., Brignardello-Petersen R. et al. (2021) ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv., 5(1): 301–325. DOI: 10.1182/bloodadvances.2020003264.
  • 12. James P.D., Connell N.T., Ameer B. et al. (2021) ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv., 5(1): 280–300. DOI: 10.1182/bloodadvances.2020003265.
  • 13. Mahmood R., Mahmood A., Khan M. et al. (2020) Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population. Blood Res., 55: 146–150. doi.org/10.5045/br.2020.2020035.
  • 14. www1.wfh.org/publications/files/pdf-1337.pdf
  • 15. Collins P., Knoebl P., Teitel J. et al. (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 105(7): 1791–1801. doi.org/10.3324/haematol.2019.230771.
  • 16. Kruse-Jarres R., Kempton C.L., Baudo F. et al. (2017) Acquired hemophilia A: Updated review of evidence and treatment guidance. Am. J. Hematol., 92(7): 695–705.